Nadja Triller

Prospective Molecular Marker Analyses of <i>EGFR</i> and <i>KRAS</i> From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

Wolfram Brugger, Nadja Triller, Maria Błasińska-Morawiec et al. · Journal of Clinical Oncology · 2011 · 276 citations · Full text

Multidrug resistance in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease

Nadja Triller, Peter Korošec, Izidor Kern et al. · Lung Cancer · 2006 · 112 citations

Drug Resistance Analysis, Health Sciences, Lung Resistance Protein +9

Rigid versus semi‐rigid thoracoscopy for the diagnosis of pleural disease: A randomized pilot study

Aleš Rozman, Luka Camlek, Mateja Marc‐Malovrh et al. · Respirology · 2013 · 73 citations

Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC

W. Brugger, Nadja Triller, Maria Błasińska-Morawiec et al. · Journal of Clinical Oncology · 2009 · 57 citations

Pathology, Pharmacotherapy, Erlotinib Maintenance Therapy +17

Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting

Mirko Lekic, Viljem Kovač, Nadja Triller et al. · Radiology and Oncology · 2012 · 41 citations · Full text